Anti-IL-2 Antibodies for Selective T Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-felt need for novel therapeutics to treat IL-2 mediated autoimmune diseases and conditions, as existing treatments are inadequate.
Innovation Solution
Development of anti-IL-2 antibodies that specifically bind to human IL-2, reducing its binding to IL-2Rα and IL-2Rβ, and inhibiting CD8+ T cell activity while promoting regulatory T cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing IL-2 treatments are used, then IL-2 mediated diseases can be treated, but treatment effectiveness is inadequate
Solution Approach 1:
The patent applies parameter changes by developing antibodies with optimized binding characteristics to IL-2. The anti-IL-2 antibodies are engineered to specifically bind IL-2 with high affinity, altering the binding parameters to achieve selective inhibition of pathogenic T cell responses while preserving regulatory T cell function. This parameter optimization resolves the contradiction by making the treatment more effective and adequate for different disease conditions.
2Reliability
If anti-IL-2 antibodies bind IL-2Rα and IL-2Rβ, then IL-2 activity is inhibited, but CD8+ T cell inhibition should be higher than Treg cell inhibition
Solution Approach 1:
The patent applies local quality by creating antibodies with non-uniform inhibition effects across different T cell types. The anti-IL-2 antibodies are designed to exhibit differential binding characteristics: they bind IL-2 and inhibit CD8+ T cell proliferation to a higher degree while having reduced inhibition of regulatory T cell (Treg) function. This localized differentiation in inhibition strength resolves the contradiction by achieving both reliable selective inhibition and a sophisticated differential mechanism.
Solution Approach 2:
The patent applies inversion by reversing the typical expectation that all T cell responses are equally suppressed. Instead of designing antibodies that uniformly inhibit all IL-2-mediated responses, the invention creates antibodies that selectively preserve Treg function while inhibiting pathogenic CD8+ T cells. This inverted approach resolves the contradiction by achieving reliable selective inhibition through a counterintuitive differential inhibition mechanism.
Data Source
AI summary
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.